AWM
CRSP icon

Accredited Wealth Management’s CRISPR Therapeutics CRSP Stock Holding History

Accredited Wealth Management’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$9.72K Sell
129
-21
-14% -$1.21K 0.01% 265
2025
Q2 		$7.3K Buy
150
+50
+50% +$1.94K 0.01% 292
2025
Q1 		$3.4K Hold
100
– – ﹤0.01% 316
2024
Q4 		$3.94K Buy
+100
New +$4.72K ﹤0.01% 308

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Accredited Wealth Management's CRSP Position: Q3 2025 in Review

Accredited Wealth Management reduced its CRISPR Therapeutics (CRSP) stake by 14% in Q3 2025, selling an estimated $1.21K and leaving 129 shares worth $9.72K. The position accounts for 0.01% of the portfolio, ranked #265.

Accredited Wealth Management first reported a position in CRSP in Q4 2024 and has held it in 4 quarters since. 440 funds tracked by Wall St. Rank hold CRSP as of Q3 2025.

  • Accredited Wealth Management held 129 shares of CRISPR Therapeutics worth $9.72K as of Q3 2025.
  • Accredited Wealth Management sold 21 CRISPR Therapeutics shares in Q3 2025, an estimated $1.21K.
  • CRISPR Therapeutics made up 0.01% of Accredited Wealth Management's portfolio in Q3 2025, its #265 holding.
  • Accredited Wealth Management first reported a position in CRISPR Therapeutics in Q4 2024 and has held it in 4 quarters since.
  • 440 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q3 2025.

Based on Accredited Wealth Management's 13F filing for Q3 2025, filed 12 Nov 2025.